Eurofarma Innovation and Growth Strategy
7
eurofarma
LEADERSHIP POSITION IN THE MAIN THERAPEUTIC CLASSES
Positioned to Further Grow
Market Share by ATC Level I
Dec/21
Market Size
(R$ bn)
18.3
7.0
12.6
3.0
7,7
6,1
22,4
11,6
8,5
8,7
21,7
Sales by Therapeutic
Class 13 (%)
Growth x
Market (1)
+4.4%
+2.8%
+5.0%
+7.0%
+8.6%
+6.6% +8.5% +7.2%
(1.8%) (6.2%)
(12.2%)
R$ 129,8 bn
Market
Position
#2
#2
#3
#4
#5
#5
#6
#6
#9 #10
9.3%
12.9%
Nervous
System
Genitourinary
System
8.2%
XXX
Anti-infective
System
9.3%
Hormonal
System
7.4%
6.6%
4%
5%
3%
23%
9%
13%
5.8%
4.2%
4.1%
6%
3.4%
14%
7%
1.9%
4%
+
MuscleBones
System
Blood
System
Digestive System Cardiovascular
& Metabolism
System
Respiratory
System
Dermatological
OthersĀ²
1- Eurofarma compounding annual growth rate from Sep/2017 to 2021 compared to sector compounding annual growth rate; 2- Others (antineoplastic and immunomodulatory agents + hospital solutions + antiparasitic, insecticide and repellent products + miscellaneous);
3- Considering ATC III classes in which the Company is present as a % of the total addressable market.
12%View entire presentation